Posted by Michael Wonder on 17 Mar 2021
Zytiga to get insurance benefit for primary therapy in metastatic hormone-sensitive prostate cancer
17 March 2021 - Janssen Korea’s prostate cancer drug Zytiga (ingredient: abiraterone acetate) will get expanded insurance benefits for the first-line treatment in patients with metastatic hormone-sensitive prostate cancer.
On Monday, the Health Insurance Review and Assessment Service said it would collect industry opinions on the revised reimbursement for drugs prescribed and administered to cancer patients until March 25.
